Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mark Sieczkarek Insider Profile
4 Followers
Mark Sieczkarek, Director at NovaBay Pharma, holds 1.16M shares in NovaBay Pharma (Ticker: NBY), holds ― shares in Mawson Infrastructure Group (Ticker: MIGI), holds 0.00 shares in Solta Medical Inc (Ticker: SLTM).
Profitable Transactions
1 out of 4 Profitable Transactions
Average Return
-23.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Mark Sieczkarek holds in companies
Most Profitable Insider Trade
The most profitable trade made by Mark Sieczkarek
Mark Sieczkarek's Trading History
NovaBay Pharma
Aug 06, 2019
Director
Uninformative Buy
―
$821.39K
Mawson Infrastructure Group
―
Director
―
―
Solta Medical Inc
Jan 27, 2014
―
Uninformative Sell
786.98K
―
List of latest transactions for each holding click on a transaction to see Mark Sieczkarek's performance on stock
You May Also Like
Mark Sieczkarek insider profile FAQ
What is the percentage of profitable transactions made by Mark Sieczkarek?
The percentage of profitable transactions made by Mark Sieczkarek is 25%.
What is the average return per transaction made by Mark Sieczkarek?
The average return per transaction made by Mark Sieczkarek is -23.60%.
What stocks does Mark Sieczkarek hold?
Mark Sieczkarek holds: NBY, MIGI, SLTM stocks.
What was Mark Sieczkarek’s latest transaction?
Mark Sieczkarek latest transaction was an Uninformative Buy of ―.
What was Mark Sieczkarek's most profitable transaction?
Mark Sieczkarek’s most profitable transaction was an Informative Buy of NBY stock on October 3, 2016. The return on the trade was 12.70%.
What is Mark Sieczkarek's role in NovaBay Pharma?
Mark Sieczkarek's role in NovaBay Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.